[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasmapheresis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasmapheresis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100648801","plasmapheresis-in-amyotrophic-lateral-sclerosis-with-autoantibody-against-nrip-2-paladin2-100648801",false,"NCT07726563","Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)","PALADIN2","Inclusion Criteria:\n\n* ALS patients above 20-year-old who have anti-NRIP autoantibody in plasma\n* Agree to receive plasmapheresis treatment\n* Agree to participate in the study and receive serial examinations\n\nExclusion Criteria:\n\n* Under permanent ventilator support\n* Cannot receive plasmapheresis treatment or serial examinations\n* Under pregnancy\n* Blood fibrinogen level below 50 mg\u002Fdl\n* Belong to special subtype of ALS, such as primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, flail leg syndrome.","ALL","20 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","10-20% of patients with ALS have anti-NRIP autoantibody and the titer of anti-NRIP autoantibody is correlated with motor functional decline and mortality in ALS. The PALADIN2 clinical trial is a single arm study, which intends to enroll 20 ALS patients having anti-NRIP autoantibody in plasma. Patients will receive 3 courses of plasmapheresis per 3 months in order to maintain low concentration of anti-NRIP autoantibody in plasma. The study will follow up these patients for another 6 months after plasmapheresis. This project will potentially confirm the efficacy and safety of plasmapheresis for ALS patients having anti-NRIP autoantibody.",[26,27,28],"Amyotrophic Lateral Sclerosis (ALS)","Autoantibody","Plasmapheresis",[30,31,32],"amyotrophic lateral sclerosis","anti-NRIP autoantibody","plasmapheresis","RECRUITING","2026-07-21",{"date":36,"type":37},"2026-07-24","ACTUAL",{"date":39,"type":37},"2026-05-19",{"date":41,"type":20},"2029-07-31",{"name":43,"class":44},"National Taiwan University Hospital","OTHER"]